Systemic Lupus Erythematous SLE Drugs Market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Systemic</strong> <strong>Lupus</strong><br />
<strong>Erythematous</strong> <strong>SLE</strong><br />
<strong>Drugs</strong> <strong>Market</strong><br />
Share, Global Trends,<br />
Analysis, Research, Report,<br />
Opportunities,<br />
Segmentation and Forecast,<br />
2015<br />
Future <strong>Market</strong> Insights<br />
www.futuremarketinsights.com<br />
sales@futuremarketinsights.com
Future <strong>Market</strong> Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting<br />
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,<br />
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.<br />
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.<br />
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and<br />
Retail.<br />
We have a global presence with delivery centers across India specializing in providing global research reports and country<br />
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.<br />
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for<br />
our client.<br />
Research Capabilities<br />
• Customized Research<br />
• Syndicated Research<br />
• Investment Research<br />
• Social Media Research<br />
Sector Coverage<br />
• Automotive and Transportation<br />
• Electronics, Semiconductor, and ICT<br />
• Retail and Consumer Products<br />
• Industrial Automation and Equipment<br />
• Chemicals & Materials<br />
• Food and Beverages<br />
• Services and Utilities<br />
• Energy, Mining, Oil, and Gas<br />
Customized<br />
Research<br />
Syndicated<br />
Research<br />
Investment<br />
Research<br />
Social Media<br />
Research<br />
Subscription Information<br />
For detailed subscription information please contact<br />
Hari. T (Sr. Manager - Global Business Development)<br />
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268<br />
Email: hari.t@futuremarketinsights.com
Report Description<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) is a chronic autoimmune disease which causes the<br />
immune system to mistakenly attack health body tissue. In <strong>SLE</strong>, body immune system can<br />
affect any part of the body, such as joints, organs, eyes, skin, etc. Often <strong>SLE</strong> can result in<br />
symptoms such as malar rash, discoid lesions, sub-acute cutaneous lesions,<br />
photosensitivity, oral ulcers, arthritis, serositis, nephropathy, neurologic involvement,<br />
thrombocytopenia, haemolytic anemia, fever, Raynaud’s phenomenon, livedo reticularis,<br />
thrombosis, and myositis. It is also known as a disease of flare-ups and remissions and<br />
can range from mild to life threatening severity. It is also called as drug-induced lupus<br />
erythematosus due to common observation against drugs such as isoniazid, hydralazine<br />
and procainamide. Currently, there is no complete treatment for <strong>SLE</strong>. While only two<br />
biologic agents have been approved by FDA to treat <strong>SLE</strong>, synthetic drugs are still the<br />
mainstay of therapy in <strong>SLE</strong>. Based on available evidence, azathioprine and<br />
mycophenolate mofetil are the drugs of first choice. Hydroxychloroquine should be<br />
considered an anchor drug in <strong>SLE</strong> because of the multiple beneficial effects of this agent.<br />
Browse Full Report@ http://www.futuremarketinsights.com/reports/systemic-lupuserythematous-sle-drugs-market<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> <strong>Market</strong>: Drivers & Restraints<br />
Global <strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> market is projected to grow due to high<br />
prevalence of autoimmune diseases particularly systemic lupus erythematous (<strong>SLE</strong>).<br />
Major drivers for global systemic erythematous drugs market are development of novel<br />
<strong>SLE</strong> therapies, increasing availability of bio similar drugs and increasing support for
Report Description<br />
At the same time, increasing awareness of disease diagnosis and treatment as well as<br />
consistent research and development processes for novel drug molecules are important<br />
drivers for global lupus erythematous market. Additionally, safety and quality of systemic<br />
lupus erythematous controlling therapy may possibly be a challenge for the growth of the<br />
global systemic lupus erythematous drugs market. Moreover, numerous public awareness<br />
programs targeted to increase awareness levels are also being accompanied. For<br />
instance, <strong>Lupus</strong> Foundation of America (LFA) has been implementing various projects to<br />
increase central support for <strong>SLE</strong> research and services to support people and families<br />
affected by <strong>SLE</strong>. However, serious side effectswith steroids, sensitivity with antibiotics,<br />
limited usage of Benlysta for severe <strong>SLE</strong> patients, and stringent regulatory approvals for<br />
new treatment options with better levels of efficacy and safety are obstructing the global<br />
systemic lupus erythematous drugs market.<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> <strong>Market</strong>: Segmentation<br />
The global systemic lupus erythematous drugs market is classified on the basis of<br />
molecule and region.<br />
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1149<br />
Based on type of molecule, the global systemic lupus erythematous drugs market is<br />
segmented into the following:<br />
Corticosteroids<br />
Non-Steroidal Anti-inflammatory <strong>Drugs</strong> (NSAIDs)
Report Description<br />
Anti-Inflammatories<br />
Disease-Modifying Anti-Rheumatic <strong>Drugs</strong> (DMARDs)<br />
Antimalarials<br />
BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)<br />
Immunosuppressive Agents/Immune Modulators<br />
Anticoagulants<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> <strong>Market</strong>: Overview<br />
Global systemic lupus erythematous drugs market growth is fast in North American<br />
region and is estimated to project remarkable CAGR growth throughout forecast period.<br />
In North America, the <strong>SLE</strong> is more prevalent among Hispanics, Asians, and Native<br />
Americans according to Centers for Disease Control and Prevention (CDC). The second<br />
largest and fastest growing global systemic lupus erythematous drugs market is Europe<br />
and is projected to reach nearly US$ 550 Mn and register a double digit CAGR due to<br />
higher prevalence of <strong>SLE</strong> in Europe. Among the European countries Sweden, Iceland,<br />
Spain had the highest prevalence according to <strong>Lupus</strong> Journal article, published in 2006. A<br />
drug called hydroxychloroquine being the last drug was approved by FDA in 1955 for <strong>SLE</strong><br />
treatment. Recently, a drug called belimumab has been approved by FDA after 50 years<br />
long gap specifically for <strong>SLE</strong> on March 9, 2011. It is the first ever targeted biological drug<br />
for the treatment of <strong>SLE</strong> patients developed by Human Genome Sciences Inc.
Report Description<br />
Benlysta will lead market sales in coming years because of its excellent safety profile as<br />
well as proven efficacy in clinical trials. NSAIDS such as Ibuprofen and aspirin are widely<br />
prescribed drugs for suppressing symptoms of <strong>SLE</strong>. Immunosuppressants by Roche<br />
(CellCept (Mycophenolate mofetil), by Novartis (Neoral (Cyclosporine)), by GSK (Imuran<br />
(Azathioprine)) are also commonly prescribed for <strong>SLE</strong> treatment. Additionally, the entry<br />
of four first-in-class (FIC) biologics such as Bristol-Myers Squibb’s Orencia (abatacept),<br />
atacicept, epratuzumab and LY2127399 are anticipated to show a major role in the<br />
expansion of the global systemic lupus erythematous drugs market.<br />
Request Free Report Sample@<br />
http://www.futuremarketinsights.com/reports/sample/rep-gb-1149<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> <strong>Market</strong>: Key Players<br />
The global systemic lupus erythematous drugs market key players are Anthera<br />
Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS,<br />
Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical<br />
Industries.
Thank You!<br />
To know more about us, please visit our website:<br />
www.futuremarketinsights.com<br />
For sales queries or new topics email us on:<br />
sales@futuremarketinsights.com<br />
For other queries contact: Mr. Sudip Saha<br />
Future <strong>Market</strong> Insights: 616 Corporate Way, Suite 2-9018,<br />
Valley Cottage, NY 10989, United States<br />
T: +1-347-918-3531 | D: +1-845-579-5705
Change language